Literature DB >> 4075314

Pharmacokinetics of diaziquone after three different dosage regimens.

T D Bjornsson, S C Schold, H S Friedman, D Schneider, J M Falletta.   

Abstract

Diaziquone (AZQ) is a benzoquinone derivative exhibiting significant effects against CNS tumors. This study investigates the pharmacokinetics of AZQ for three different durations of continuous iv infusions, over 20 mins, 4 hrs, and 6 hrs, in nine patients with CNS malignancies. Total AZQ doses varied from 10 to 20 mg. The average elimination half-life was 37.2 +/- 13.9 mins, the total clearance was 515 +/- 280 ml/min or 11.3 +/- 5.9 ml/min/kg, and the apparent volume of distribution by area was 26.5 +/- 14.7 L or 0.62 +/- 0.50 L/kg. Peak concentrations after the 20-min infusions (three patients) varied from 0.58 to 1.20 micrograms/ml, whereas concentrations during the 4-hr infusions (three patients) varied from 0.02 to 0.37 micrograms/ml, and during the 6-hr infusions (three patients) varied from 0.02 to 0.61 micrograms/ml. These results indicate that concentrations found to exhibit minimum inhibitory effects in in vitro cell studies are achievable during prolonged iv infusions of AZQ.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075314

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.

Authors:  R P Castleberry; A H Ragab; C P Steuber; B Kamen; S Toledano; K Starling; D Norris; P Burger; J P Krischer
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

2.  Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study.

Authors:  J M Falletta; B Cushing; S Lauer; B Bell; D H Mahoney; R Castleberry; R A Krance
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.

Authors:  W K Yung; M I Harris; J M Bruner; L G Feun
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.